Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05128994 · ClinicalTrials.gov registry record · NA
Hand Grasp Function After Spinal Cord Injury
A NA study, sponsored by Battelle Memorial Institute.
- Completed
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT05128994: Completed NA study, sponsored by Battelle Memorial Institute.
NCT05128994 is a NA study that has completed, run by Battelle Memorial Institute. The registered enrollment target is 5 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05128994, a NA study, has completed, sponsored by Battelle Memorial Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
The objective of this study is to advance personalized, portable, and non-invasive hand-grasp neuro-orthoses that restore naturalistic grasp functions for those with tetraplegia due to spinal cord injury (SCI), designed around their needs and preferences.
Primary Outcome
Semi structured interviews will involve gaining participants opinions on the strengths and weaknesses of the system
Interventions
- DEVICE User-controlled FES system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2022-04-05 |
| Est. Completion | 2024-07-31 |
| Phase | NA |
What the finished NCT05128994 record still lists
NCT05128994 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which User-controlled FES system is the first listed.
NCT05128994 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05128994 about?
NCT05128994 is a clinical study titled "Hand Grasp Function After Spinal Cord Injury". The objective of this study is to advance personalized, portable, and non-invasive hand-grasp neuro-orthoses that restore naturalistic grasp functions for those with tetraplegia due to spinal cord injury (SCI), designed around their needs and preferences.
What is the current status of trial NCT05128994?
This trial is currently completed. It is a NA study. The enrollment target is 5 participants. The study started on 2022-04-05. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT05128994?
The interventions under investigation include: User-controlled FES system (DEVICE).
Who is sponsoring clinical trial NCT05128994?
This trial is sponsored by Battelle Memorial Institute, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05128994's enrollment target sits among peer trials
5 1988th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-07-11
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT04558619 · started 2022-04-05 · NA
Exploring the Feasibility of Kōmmour Prenatal to Reduce Maternal and Infant Health Disparities
- NCT04627428 · started 2022-04-05 · Phase 1
Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)
- NCT05895006 · started 2022-04-05 · NA
A Neurosensory Account of Anxiety and Stress (Study 1)
- NCT04966481 · started 2022-04-06 · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor